Danusertib, an aurora kinase inhibitor

Bibliography

• Cheung CHA, Coumar MS, Hsieh HP, Chang JY. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs 2009;18:379-98
   PubMed Web of Science ®Google Scholar
• Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;369:643-9.
   Web of Science ®Google Scholar
• Schmidt M, Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat 2007;10:162-81
   PubMed Web of Science ®Google Scholar
• Kitzen JJEM, de Jonge MJA, Verweij J. Aurora kinase inhibitors. Crit Rev Oncol Hematol 2010;73:99-110
   PubMed Web of Science ®Google Scholar
• Giet R, Petretti C, Pringent C. Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol 2005;15:241-50
   PubMed Web of Science ®Google Scholar
• Glover DM, Leibowitz MH, McLean DA, Parry H. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 1995;81:95-105.
   PubMed Web of Science ®Google Scholar
• Bischoff JR, Anderson L, Zhu Y, A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17:3052-65
   PubMed Web of Science ®Google Scholar
• Carpinelli P, Moll J. Aurora kinases and their inhibitors: more than one target and one drug. Adv Exp Med Biol 2008;610:54-73
   PubMed Web of Science ®Google Scholar
• Brown JR, Koretke KK, Birkeland ML, Evolutionary relationships of Aurora kinases: Implications for model organism studies and the development of anti-cancer drugs. BMC Evol Biol 2004; 4:39-48
   PubMed Web of Science ®Google Scholar
• Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4: 842-54
   PubMed Web of Science ®Google Scholar
• Bisshoff JR, Plowman GD. The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol 1999;9:454-9
   PubMed Web of Science ®Google Scholar
• Ke YW, Dou Z, Zhang J, Yao XB. Function and regulation of Aurora/Ipl1p kinase family in cell division. Cell Res 2003;13: 69-81
   PubMed Web of Science ®Google Scholar
• Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4:927-36
   PubMed Web of Science ®Google Scholar
• Katayama H, Ota T, Jisaki F, Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 1999; 91:1160-2
   PubMed Web of Science ®Google Scholar
• Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 2065-71
   PubMed Web of Science ®Google Scholar
• Dar AA, Zaika A, Piazuelo MB, Frequent overexpression of aurorakinase A in upper gastro-intestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 2008;112:1688-98
   PubMed Web of Science ®Google Scholar
• Reiter R, Gais P, Jutting U, Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12:5136-41
   PubMed Web of Science ®Google Scholar
• Karthigeyan D, Prasad SB, Shandilya J, Biology of Aurora A kinase: implications in cancer manifestation and therapy. Med Res Rev 2010; 31:757-93
   Google Scholar
• Warner SL, Bearss DJ, Han H, von Hoff DD. Targeting Aurora-2 kinase in cancer. Mol Cancer Ther 2003; 2:589-95.
   PubMed Web of Science ®Google Scholar
• Li JJ, Li SA. Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. Pharmacol Ther 2006;111:974-84
   PubMed Web of Science ®Google Scholar
• Mao JH, Wu D, Perez-Losada J, Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell 2007; 11:161-73
   PubMed Web of Science ®Google Scholar
• Ouchi M, Fujiuchi N, Sasai K, BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 2004; 279:19643-8
   PubMed Web of Science ®Google Scholar
• Wang X, Zhou YX, Qiao W, Overexpression of Aurora kinase A in mouse mammary epithelium induces genetic instability precedeing mammary tumour formation. Oncogene 2006;25:7148-58
   PubMed Web of Science ®Google Scholar
• Vader G, Medema RH, Lens SM. The chromosomal passenger complex: guiding aurora-B through mitosis. J Cell Biol 2006;173:833-7
   PubMed Web of Science ®Google Scholar
• Moore AS, Blagg J, Linardopoulos S, Pearson ADJ. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 2010;24:671-8
   PubMed Web of Science ®Google Scholar
• Dewar H, Tanaka K, Nasmyth K, Tanaka TU. Tension between the two kinetochores suffices for their bioorientation on the mitotic spindle. Nature 2004;428:93-7
   PubMed Web of Science ®Google Scholar
• Goto H, Yasui Y, Kawajiri A, Aurora-B regulates the cleavage furrow-specific vimentin phosphorylation in the cytokinetic process. J Biol Chem 2003;278:8526-30
   PubMed Web of Science ®Google Scholar
• Lipp JJ, Hirota T, Poser I. Aurora B controls the association of condensin I but not condensin II with mitotic chromosomes. J Cell Sci 2007;120:1245-55
   PubMed Web of Science ®Google Scholar
• Tang CJ, Lin CY, Tang TK. Dynamic localization and functional implications of Aurora-C kinase during male mouse meiosis. Dev Biol 2006;290:398-410
   PubMed Web of Science ®Google Scholar
• Yang KT, Li SK, Chang CC, Aurora-C kinase deficiency causes cytokinesis failure in meiosis I and production of large polyploid oocytes in mice. Mol Biol Cell 2010;21:2371-83
   Google Scholar
• Sasai K, Katayama H, Stenoien D, Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton 2004;59:249-63
   PubMed Web of Science ®Google Scholar
• Carpinelli P, Ceruti R, Giorgini ML, PHA-739358, a potent inhibitor of aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6:3158-68.
   PubMed Web of Science ®Google Scholar
• Fancelli D, Moll J, Varasi M, 1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 2006;49:7247-51.
   PubMed Web of Science ®Google Scholar
• Gontarewicz A, Balabanov S, Keller G, Simultaneous targeting of aurora kinases and Bcr-Abl kinase by the small molecule inhibitor danusertib is effective against imatinib-resistant BCR-ABL mutations including T3151. Blood 2008; 111:4355-64.
   PubMed Web of Science ®Google Scholar
• Gontarewicz A, Brummendorf TH. Danusertib (formerly PHA-739358) - A novel combined pan-aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Recent Results Cancer Res 2010;184:199-214
   PubMedGoogle Scholar
• Clarkson B, Strife A, Wisniewski D, Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia 2003;17:1211-62
   PubMed Web of Science ®Google Scholar
• Balabanov S, Gontarewicz A, Keller G, Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor danusertib in BCR-ABL-positive cells in vitro. PLoS ONE 2011;6(4):e19164
   PubMed Web of Science ®Google Scholar
• Bongarzone I, Vigneri P, Mariani L, Ret/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res 1998;4:223-8
   PubMed Web of Science ®Google Scholar
• Sjoblom T, Jones S, Wood L, The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-74
   PubMed Web of Science ®Google Scholar
• Dionne CA, Camaratto AM, Jani JP, Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751(KT6587). Clin Cancer Res 1998; 4:1887-98
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Salvatore D, Santoro M, Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 1995; 207:1022-8
   PubMed Web of Science ®Google Scholar
• Greenberg NM, DeMayo F, Finegold MJ, Prostate cancer in a transgenic Mouse. Proc Natl Acad Sci USA 1995;92:3439-43
   PubMed Web of Science ®Google Scholar
• Beltran H, Rickman D, Park K, Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets. J Clin Oncol 2011;29:abstract 4536
   Google Scholar
• Benten D, Keller G, Quaas A, Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 2009;11:934-44
   PubMed Web of Science ®Google Scholar
• Steeghs N, Eskens FA, Gelderblom H, Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol 2009; 27: 5094-101.
   PubMed Web of Science ®Google Scholar
• Cohen RB, Jones SF, Aggarwal C, A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009;15: 6694-701.
   PubMed Web of Science ®Google Scholar
• Steeghs N, Mathijssen RHJ, Wessels JAM, Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. Invest New Drugs 2011; 29:953-62
   PubMed Web of Science ®Google Scholar
• Rosen PJ, Tolcher AW, Lee P, Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors. J Clin Oncol 2010; 28(15s): abstract 3066
   Google Scholar
• Cortes-Franco J, Dombret H, Schafhausen P, Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 2009; 114: abstract 864
   Google Scholar
• NCT00335868. PHA-739358 in treating patients with Chronic Myelogenous Leukemia that relapsed after Imatinib Mesylate or c-ABL therapy. Available from: www.ClinicalTrials.gov
   Google Scholar
• Paquette RL, Shah NP, Sawyers CL, PHA-739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I Mutations of BCR-ABL. Blood 2007; 110: abstract 1030.
   Google Scholar
• Gallerani E, Delord J, Schoffski P, Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC). J Clin Oncol 2010; 28(15s): abstract 5014.
   Google Scholar
• Laffranchi B, De Jonge MJ, Bajetta E, Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC). J Clin Oncol 2010;28:abstract e13558.
   Google Scholar
• Bleuse JP, Meulenbeld HJ, Vinci EM, Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2011;29: abstract 4628.
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16
   PubMed Web of Science ®Google Scholar
• Cheung CH, Coumar MS, Chang JY, Hsieh HP. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009 – 10). Expert Opin Ther Patents 2011; 21:857-84
   PubMed Web of Science ®Google Scholar
• Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 2011;8:244-50.
   PubMed Web of Science ®Google Scholar